168 related articles for article (PubMed ID: 28421416)
1. Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Cho J; Kim SY; Kim YJ; Sim MH; Kim ST; Kim NKD; Kim K; Park W; Kim JH; Jang KT; Lee J
Clin Transl Oncol; 2017 Oct; 19(10):1247-1252. PubMed ID: 28421416
[TBL] [Abstract][Full Text] [Related]
2. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
3. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
Todd JR; Becker TM; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
[TBL] [Abstract][Full Text] [Related]
4. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
5. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
[No Abstract] [Full Text] [Related]
6. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
[TBL] [Abstract][Full Text] [Related]
7. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
[TBL] [Abstract][Full Text] [Related]
8. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
Murer C; Kränzlin-Stieger P; French LE; Dummer R; Goldinger SM
Melanoma Res; 2017 Aug; 27(4):396-398. PubMed ID: 28410286
[TBL] [Abstract][Full Text] [Related]
10. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
12. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
Vita M; Tisserand JC; Chauvot de Beauchêne I; Panel N; Tchertanov L; Agopian J; Mescam-Mancini L; Fouet B; Fournier B; Dubreuil P; Bertucci F; De Sepulveda P
JAMA Dermatol; 2014 Dec; 150(12):1345-9. PubMed ID: 25317746
[TBL] [Abstract][Full Text] [Related]
13. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
14. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Ponatinib as a Potent Agent against
Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
[No Abstract] [Full Text] [Related]
16. Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.
Abdou Y; Kapoor A; Hamad L; Ernstoff MS
Medicine (Baltimore); 2019 Nov; 98(44):e17769. PubMed ID: 31689840
[TBL] [Abstract][Full Text] [Related]
17. Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab.
Komatsu-Fujii T; Nomura M; Otsuka A; Ishida Y; Doi K; Matsumoto S; Muto M; Kabashima K
J Dermatol; 2019 Jun; 46(6):e203-e204. PubMed ID: 30614559
[No Abstract] [Full Text] [Related]
18. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
Takahashi T; Elzawahry A; Mimaki S; Furukawa E; Nakatsuka R; Nakamura H; Nishigaki T; Serada S; Naka T; Hirota S; Shibata T; Tsuchihara K; Nishida T; Kato M
Genes Chromosomes Cancer; 2017 Apr; 56(4):303-313. PubMed ID: 27997714
[TBL] [Abstract][Full Text] [Related]
19. C-kit-mutated melanomas: the Chinese experience.
Si L; Guo J
Curr Opin Oncol; 2013 Mar; 25(2):160-5. PubMed ID: 23299198
[TBL] [Abstract][Full Text] [Related]
20. Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb.
Yamaguchi M; Harada K; Ando N; Kawamura T; Shibagaki N; Shimada S
Clin Exp Dermatol; 2011 Mar; 36(2):174-7. PubMed ID: 20545949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
